All Stories

  1. Oligonucleotide‐Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases

    Article • Hepatology, March 2021, Wolters Kluwer Health

    Professor Eric J Lawitz

  2. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

    Article • Expert Opinion on Investigational Drugs, September 2019, Taylor & Francis

    Professor Eric J Lawitz, George R. Cowgill Professor of Medicine and Physiology Gerald I Shulman

  3. Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment

    Article • Hepatology Communications, March 2019, Wolters Kluwer Health

    Professor Eric J Lawitz

  4. Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes

    Article • Hepatology Communications, June 2018, Wolters Kluwer Health

    Professor Eric J Lawitz

  5. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C

    Article • Expert Review of Gastroenterology & Hepatology, December 2017, Taylor & Francis

    Professor Eric J Lawitz

  6. Novel treatments for chronic hepatitis C: closing the remaining gaps

    Article • Current Opinion in Pharmacology, December 2017, Elsevier

    Professor Eric J Lawitz

  7. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus

    Article • Hepatology, May 2017, Wiley

    Professor Eric J Lawitz

  8. Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial

    Article • Hepatology, December 2016, Wiley

    Professor Eric J Lawitz

  9. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

    Article • Antimicrobial Agents and Chemotherapy, June 2016, ASM Journals

    Professor Eric J Lawitz

  10. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

    Article • Leukemia & Lymphoma, June 2016, Taylor & Francis

    Professor Eric J Lawitz

  11. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

    Article • Gastroenterology, June 2016, Elsevier

    Professor Eric J Lawitz

  12. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir

    Article • Gastroenterology, June 2016, Elsevier

    Professor Eric J Lawitz

  13. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

    Article • Hepatology, February 2016, Wiley

    Professor Eric J Lawitz

  14. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies

    Article • Antiviral Therapy, January 2016, International Medical Press

    Professor Eric J Lawitz

  15. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

    Article • New England Journal of Medicine, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  16. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Article • New England Journal of Medicine, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  17. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

    Article • Antimicrobial Agents and Chemotherapy, December 2015, ASM Journals

    Professor Eric J Lawitz

  18. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients

    Article • Liver International, December 2015, Wiley

    Professor Eric J Lawitz

  19. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions

    Article • The Journal of Infectious Diseases, November 2015, Oxford University Press (OUP)

    Professor Eric J Lawitz

  20. Next-Generation Regimens

    Article • Clinics in Liver Disease, November 2015, Elsevier

    Professor Eric J Lawitz

  21. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment

    Article • Journal of Hepatology, October 2015, Elsevier

    Dr Allison M Kitten, Professor Eric J Lawitz

  22. Management of patients with hepatitis C virus resistance-associated variants to NS5A inhibitors: Where are we now?

    Article • Clinical Liver Disease, October 2015, Wiley

    Professor Eric J Lawitz

  23. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

    Article • Gastroenterology, October 2015, Elsevier

    Professor Eric J Lawitz

  24. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.

    Article • Clinical Infectious Diseases, September 2015, Oxford University Press (OUP)

    Professor Eric J Lawitz

  25. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

    Article • Journal of Hepatology, September 2015, Elsevier

    Professor Eric J Lawitz

  26. Abstract B20: Pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment: Results from an open-label, multicenter study.

    Article • Clinical Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Professor Eric J Lawitz

  27. Development of sofosbuvir for the treatment of hepatitis C virus infection

    Article • Annals of the New York Academy of Sciences, July 2015, Wiley

    Professor Eric J Lawitz

  28. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C

    Article • Journal of Viral Hepatitis, June 2015, Wiley

    Professor Eric J Lawitz

  29. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

    Article • Hepatology, May 2015, Wiley

    Professor Eric J Lawitz

  30. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection

    Article • Journal of Hepatology, May 2015, Elsevier

    Professor Eric J Lawitz

  31. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

    Article • Hepatology, April 2015, Wiley

    Professor Eric J Lawitz

  32. Tu1033 Evaluation of Access to Care in Patients Prescribed Sofosbuvir-Containing Regimens: Data From the TRIO Network

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  33. Tu1023 Efficacy Evaluation of 24 Week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV Patients; Data From the TRIO Network

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  34. Tu1018 Sofosbuvir-Based Regimens for Patients With Hepatitis C Virus Genotype 3 Infection: Summary Results From the VALENCE, LONESTAR-2, and ELECTRON-2 Studies

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  35. Tu1017 Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients Over 70 Years of Age vs Younger HCV Patients; Data From the TRIO Network

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  36. 1011 Final Evaluation of 955 HCV Patients Treated With 12 Week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  37. Tu1024 Plasma Interferon-γ-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  38. 364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  39. 1016 All-Oral 12-Week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Treatment-Experienced Patients Infected With HCV Genotype (GT) 3: A Subanalysis of the Ally-3 Phase 3 Study

    Article • Gastroenterology, April 2015, Elsevier

    Professor Eric J Lawitz

  40. Accuracy of Fibroscan, Compared With Histology, in Analysis of Liver Fibrosis in Patients With Hepatitis B or C: A United States Multicenter Study

    Article • Clinical Gastroenterology and Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  41. P0711 : Genome-wide association study of response to sofosbuvir-ribavirin treatment in GT2/3 HCV patients

    Article • Journal of Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  42. O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks

    Article • Journal of Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  43. P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population

    Article • Journal of Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  44. P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network

    Article • Journal of Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  45. P0769 : Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection

    Article • Journal of Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  46. P0787 : Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years of age vs younger HCV patients; Data from the Trio network

    Article • Journal of Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  47. P0898 : TD-6450, A next generation once-daily NS5A inhibitor, has potent antiviral activity following a 3-day monotherapy study in genotype 1 HCV infection

    Article • Journal of Hepatology, April 2015, Elsevier

    Professor Eric J Lawitz

  48. All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

    Article • Hepatology, March 2015, Wiley

    Professor Eric J Lawitz

  49. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previo...

    Article • The Lancet, March 2015, Elsevier

    Professor Eric J Lawitz

  50. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection

    Article • Journal of Infection, February 2015, Elsevier

    Professor Eric J Lawitz

  51. Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection

    Article • Gastroenterology, February 2015, Elsevier

    Professor Eric J Lawitz

  52. Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

    Article • Hepatology, January 2015, Wiley

    Professor Eric J Lawitz

  53. A randomized, placebo‐controlled study of the NS 5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

    Article • Journal of Viral Hepatitis, December 2014, Wiley

    Professor Eric J Lawitz

  54. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

    Article • Journal of Hepatology, December 2014, Elsevier

    Professor Eric J Lawitz

  55. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

    Article • Hepatology, November 2014, Wiley

    Professor Eric J Lawitz

  56. Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study

    Article • Liver International, November 2014, Wiley

    Professor Thomas Berg, Professor Eric J Lawitz

  57. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    Article • The Lancet, November 2014, Elsevier

    Dr Joseph K Lim, Professor Eric J Lawitz

  58. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients

    Article • Antiviral Research, November 2014, Elsevier

    Professor Eric J Lawitz

  59. Clinical andIn VitroResistance to GS-9669, a Thumb Site II Nonnucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase

    Article • Antimicrobial Agents and Chemotherapy, August 2014, ASM Journals

    Professor Eric J Lawitz

  60. Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C

    Article • Clinical Gastroenterology and Hepatology, August 2014, Elsevier

    Professor Eric J Lawitz

  61. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

    Article • Gut, July 2014, BMJ

    Professor Eric J Lawitz

  62. Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

    Article • Journal of Gastroenterology and Hepatology, July 2014, Wiley

    Professor Eric J Lawitz

  63. Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis

    Article • Clinical Gastroenterology and Hepatology, June 2014, Elsevier

    Professor Eric J Lawitz

  64. Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

    Article • Gastroenterology, June 2014, Elsevier

    Professor Eric J Lawitz

  65. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection

    Article • Hepatology, May 2014, Wolters Kluwer Health

    Professor Eric J Lawitz

  66. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

    Article • New England Journal of Medicine, May 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  67. 763 All-Oral Therapy With Daclatasvir in Combination With Asunaprevir and Bms-791325 for Treatment-Naive Patients With Chronic HCV Genotype 4 Infection

    Article • Gastroenterology, May 2014, Elsevier

    Professor Eric J Lawitz

  68. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4

    Article • Journal of Hepatology, May 2014, Elsevier

    Professor Eric J Lawitz

  69. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens

    Article • Hepatology, April 2014, Wiley

    Professor Eric J Lawitz

  70. Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

    Article • New England Journal of Medicine, April 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  71. Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

    Article • Antimicrobial Agents and Chemotherapy, April 2014, ASM Journals

    Professor Eric J Lawitz

  72. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)

    Article • Journal of Hepatology, April 2014, Elsevier

    Professor Eric J Lawitz

  73. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response

    Article • Journal of Hepatology, April 2014, Elsevier

    Professor Eric J Lawitz

  74. P1097 LONG-TERM SAFETY AND EFFICACY OF MIRAVIRSEN IN CHRONIC HEPATITIS C PATIENTS

    Article • Journal of Hepatology, April 2014, Elsevier

    Professor Eric J Lawitz

  75. P1114 PATIENT-REPORTED OUTCOMES (PROS) IN CHRONIC HEPATITIS C PATIENTS WITH CIRRHOSIS TREATED WITH SOFOSBUVIR (SOF) CONTAINING REGIMENS

    Article • Journal of Hepatology, April 2014, Elsevier

    Professor Eric J Lawitz

  76. P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT

    Article • Journal of Hepatology, April 2014, Elsevier

    Professor Eric J Lawitz

  77. P719 INDEPENDENT PREDICTORS OF PATIENT-REPORTED OUTCOMES (PROS) AND QUALITY OF LIFE (QOL) IN CHRONIC HEPATITIS C PATIENTS RECEIVING INTERFERON (IFN)-FREE VERSUS IFN-CONTAINING REGIMENS WITH SOFOSBUVIR (SOF)

    Article • Journal of Hepatology, April 2014, Elsevier

    Professor Eric J Lawitz

  78. P1229 LOW PERSISTENCE OF RESISTANCE-ASSOCIATED VARIANTS AFTER 3 DAYS OF MONOTHERAPY WITH NS5B NNI SITE II INHIBITOR GS-9669 IN GENOTYPE 1 HCV PATIENTS

    Article • Journal of Hepatology, April 2014, Elsevier

    Professor Eric J Lawitz

  79. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

    Article • Journal of Hepatology, March 2014, Elsevier

    Professor Eric J Lawitz

  80. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy

    Article • Gastroenterology, February 2014, Elsevier

    Professor Eric J Lawitz

  81. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

    Article • The Lancet, February 2014, Elsevier

    Professor Eric J Lawitz

  82. Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

    Article • Gastroenterology, February 2014, Elsevier

    Professor Eric J Lawitz

  83. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment

    Article • The Journal of Clinical Pharmacology, January 2014, Wiley

    Professor Eric J Lawitz

  84. Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

    Article • New England Journal of Medicine, January 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  85. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

    Article • New England Journal of Medicine, January 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  86. Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938

    Article • Antiviral Therapy, January 2014, International Medical Press

    Professor Eric J Lawitz

  87. Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor

    Article • Antiviral Therapy, January 2014, International Medical Press

    Professor Eric J Lawitz

  88. Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C

    Article • Antiviral Therapy, January 2014, International Medical Press

    Professor Eric J Lawitz

  89. Predictors of consent to pharmacogenomics testing in the IDEAL study

    Article • Pharmacogenetics and Genomics, November 2013, Wolters Kluwer Health

    Professor Eric J Lawitz

  90. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial

    Article • Gastroenterology, November 2013, Elsevier

    Professor Eric J Lawitz

  91. Health-Related Quality of Life (HRQL) in Chronic Hepatitis C (CH-C) Patients Treated with Sofosbuvir Containing Interferon-Free Regimens

    Article • Value in Health, November 2013, Elsevier

    Professor Eric J Lawitz

  92. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

    Article • Hepatology, October 2013, Wiley

    Professor Eric J Lawitz

  93. Real World Experience in the Era of First Generation Protease Inhibitors in the Treatment of Hepatitis C

    Article • Current Hepatology Reports, October 2013, Springer Science + Business Media

    Professor Eric J Lawitz

  94. Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection

    Article • Gastroenterology, October 2013, Elsevier

    Professor Eric J Lawitz

  95. Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis C Genotype 1

    Article • Journal of Clinical Gastroenterology, October 2013, Wolters Kluwer Health

    Professor Eric J Lawitz

  96. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

    Article • Antiviral Research, September 2013, Elsevier

    Professor Eric J Lawitz

  97. Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

    Article • Antimicrobial Agents and Chemotherapy, July 2013, ASM Journals

    Professor Eric J Lawitz

  98. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment

    Article • Journal of Hepatology, July 2013, Elsevier

    Professor Eric J Lawitz

  99. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

    Article • Journal of Hepatology, July 2013, Elsevier

    Professor Eric J Lawitz

  100. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

    Article • The Lancet, June 2013, Elsevier

    Professor Eric J Lawitz

  101. A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

    Article • PLoS ONE, May 2013, PLOS

    Professor Eric J Lawitz

  102. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

    Article • New England Journal of Medicine, May 2013, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  103. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

    Article • New England Journal of Medicine, May 2013, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  104. Treatment of HCV Infection by Targeting MicroRNA

    Article • New England Journal of Medicine, May 2013, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  105. Sa2073 SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders

    Article • Gastroenterology, May 2013, Elsevier

    Professor Eric J Lawitz

  106. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure

    Article • Journal of Hepatology, May 2013, Elsevier

    Professor Eric J Lawitz

  107. 869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial

    Article • Gastroenterology, May 2013, Elsevier

    Professor Eric J Lawitz

  108. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

    Article • The Lancet Infectious Diseases, May 2013, Elsevier

    Professor Eric J Lawitz

  109. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  110. 1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  111. 876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  112. 842 SOFOSBUVIR SAFETY AND TOLERABILITY IN 741 PATIENTS TREATED FOR UP TO 24 WEEKS

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  113. 106 SUSTAINED VIRAL RESPONSE AND SAFETY OF MK-7009 IN CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON AND RIBAVIRIN TREATMENT

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  114. 470 CHANGES IN INTERFERON-GAMMA INDUCIBLE PROTEIN-10 IN TREATMENT-NAÏVE VERSUS TREATMENT-EXPERIENCED PATIENTS GIVEN AN ALL-ORAL ANTI-HCV REGIMEN

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  115. 1192 VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  116. 1196 ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  117. 845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  118. 847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  119. 848 HIGH CONCORDANCE OF SVR4, SVR12, AND SVR24 IN PATIENTS WITH HCV INFECTION WHO HAVE RECEIVED TREATMENT WITH SOFOSBUVIR

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  120. 1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  121. 1193 RESISTANCE ANALYSES USING DEEP AND POPULATION SEQUENCING AFTER 3 DAY MONOTHERAPY WITH GS-9669, A NOVEL NON-NUCLEOSIDE NS5B INHIBITOR IN GENOTYPE 1 HCV PATIENTS

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Eric J Lawitz

  122. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR)

    Article • Journal of Viral Hepatitis, March 2013, Wiley

    Professor Eric J Lawitz

  123. Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure

    Article • Journal of Hepatology, March 2013, Elsevier

    Professor Eric J Lawitz

  124. Cyclophilin Inhibitors for Hepatitis C Therapy

    Article • Clinics in Liver Disease, February 2013, Elsevier

    Professor Eric J Lawitz

  125. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C

    Article • New England Journal of Medicine, January 2013, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  126. Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection

    Article • Clinical Gastroenterology and Hepatology, January 2013, Elsevier

    Professor Eric J Lawitz

  127. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial F

    Article • Antiviral Chemistry and Chemotherapy, January 2013, International Medical Press

    Professor Eric J Lawitz

  128. Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection

    Article • Antimicrobial Agents and Chemotherapy, December 2012, ASM Journals

    Professor Eric J Lawitz

  129. Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients

    Article • Antimicrobial Agents and Chemotherapy, August 2012, ASM Journals

    Professor Eric J Lawitz

  130. Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection

    Article • Clinical Gastroenterology and Hepatology, August 2012, Elsevier

    Professor Eric J Lawitz

  131. Non-interferon Therapies for Hepatitis C

    Article • Current Hepatology Reports, July 2012, Springer Science + Business Media

    Professor Eric J Lawitz

  132. Mo1919 Chronic Aminotransferase Elevation Confounds Transient Elastography in HCV Patients With Early Stage Fibrosis

    Article • Gastroenterology, May 2012, Elsevier

    Professor Eric J Lawitz

  133. Sa1070 Depression is as Early Complication of HCV Treatment: Results From EMPOWER (a Randomized, Open-Label 12-Week Comparison in 133 Patients)

    Article • Gastroenterology, May 2012, Elsevier

    Professor Eric J Lawitz

  134. 836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results

    Article • Gastroenterology, May 2012, Elsevier

    Professor Eric J Lawitz

  135. 1211 NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HCV GT-1 PATIENTS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Eric J Lawitz

  136. 1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Eric J Lawitz

  137. 1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Eric J Lawitz

  138. 1153 THE EFFECT OF HEPATIC IMPAIRMENT ON THE SAFETY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-938 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Eric J Lawitz

  139. 12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Eric J Lawitz

  140. 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Eric J Lawitz

  141. 1215 PERSISTENCE OF NS5A GS-5885 DRUG RESISTANCE MUTATIONS FOLLOWING 3 DAYS OF MONOTHERAPY IN GENOTYPE-1 HCV PATIENTS IS DEPENDENT ON THE HCV SUBTYPE AND SPECIFIC MUTATION

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Eric J Lawitz

  142. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients

    Article • Journal of Hepatology, February 2012, Elsevier

    Professor Eric J Lawitz

  143. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

    Article • New England Journal of Medicine, January 2012, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  144. A Phase 1, randomized, placebo-controlled, three-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients

    Article • Antiviral Therapy, January 2012, International Medical Press

    Professor Eric J Lawitz

  145. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

    Article • Hepatology, December 2011, Wiley

    Professor Eric J Lawitz

  146. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

    Article • Patient Preference and Adherence, November 2011, Taylor & Francis

    Madam Nathalie Lambert, Professor Eric J Lawitz

  147. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

    Article • Gut, August 2011, BMJ

    Professor Eric J Lawitz

  148. The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

    Article • Clinics in Liver Disease, August 2011, Elsevier

    Professor Eric J Lawitz

  149. Telaprevir for Retreatment of HCV Infection

    Article • New England Journal of Medicine, June 2011, New England Journal of Medicine (NEJM/MMS)

    Professor Daniel D Shouval, Professor Eric J Lawitz, Prof. Dr. Bart van Hoek

  150. Subanalysen des Telepravir-Lead-In-Arms in der REALIZE-Studie: Response in Woche 4 ersetzt nicht vorherige Kategorisierung als Nullresponder

    Article • Seminars in Musculoskeletal Radiology, May 2011, Thieme Publishing Group

    Professor Eric J Lawitz

  151. Telaprevir-basierte Therapie bei HCV-infizierten G1-Patienten, die auf Peginterferon/Ribavirin als Nullresponder, partielle Responder oder Relapser reagiert hatten: Abschlussergebnisse der REALIZE-Studie

    Article • Seminars in Musculoskeletal Radiology, May 2011, Thieme Publishing Group

    Professor Eric J Lawitz

  152. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

    Article • New England Journal of Medicine, March 2011, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  153. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy

    Article • Antiviral Research, March 2011, Elsevier

    Professor Eric J Lawitz

  154. 472 PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Eric J Lawitz

  155. 1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Eric J Lawitz

  156. 1235 PSI-352938, A NOVEL PURINE NUCLEOTIDE ANALOG, EXHIBITS POTENT ANTIVIRAL ACTIVITY AND NO EVIDENCE OF RESISTANCE IN PATIENTS WITH HCV GENOTYPE 1 OVER 7 DAYS

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Eric J Lawitz

  157. 444 SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Eric J Lawitz

  158. 445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Eric J Lawitz

  159. 1220 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Eric J Lawitz

  160. 61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Eric J Lawitz

  161. Open-label Phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients

    Article • Antiviral Therapy, January 2011, International Medical Press

    Professor Eric J Lawitz

  162. Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

    Article • Gastroenterology, October 2010, Elsevier

    Professor Eric J Lawitz

  163. Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1

    Article • Gastroenterology, October 2010, Elsevier

    Professor Eric J Lawitz

  164. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

    Article • Hepatology, August 2010, Wiley

    Professor Eric J Lawitz

  165. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

    Article • The Lancet, August 2010, Elsevier

    Professor Eric J Lawitz

  166. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Article • Gastroenterology, July 2010, Elsevier

    Professor Eric J Lawitz, Thierry Poynard

  167. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

    Article • Hepatology, May 2010, Wiley

    Professor Eric J Lawitz

  168. 2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Eric J Lawitz

  169. 2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Eric J Lawitz

  170. 272 EARLY VIRAL RESPONSE OF CONTROLLED-RELEASE INTERFERON ALPHA2B AND RIBAVIRIN VS. PEGYLATED-INTERFERON ALPHA2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 12 WEEK RESULTS (SELECT-2 TRIAL)

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Eric J Lawitz

  171. 273 SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Eric J Lawitz

  172. 31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Eric J Lawitz

  173. 32 A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERS

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Eric J Lawitz

  174. Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized, Multicenter, Open-Label Study

    Article • Clinical Gastroenterology and Hepatology, January 2010, Elsevier

    Professor Eric J Lawitz

  175. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

    Article • New England Journal of Medicine, August 2009, New England Journal of Medicine (NEJM/MMS)

    Professor Eric J Lawitz

  176. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders

    Article • Hepatology, August 2009, Wiley

    Professor Eric J Lawitz

  177. Evaluation of VCH-759 monotherapy in hepatitis C infection

    Article • Journal of Hepatology, July 2009, Elsevier

    Professor Eric J Lawitz

  178. 748 United States Multicenter Study of Ultrasonic TRANSIENT ELASTOGRAPHY (FibroScan) for the Diagnosis of Cirrhosis and Fibrosis in Patients with Hepatitis B and C

    Article • Gastroenterology, May 2009, Elsevier

    Professor Eric J Lawitz

  179. 622 SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  180. 627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  181. 628 RANDOMIZED TRIAL COMPARING SYSTEMIC AND LOCAL REACTIONS TO CONTROLLED-RELEASE INTERFERON ALPHA2B AND PEGYLATED-INTERFERON ALPHA2B IN HEPATITIS C PATIENTS WHO FAILED PRIOR TREATMENT

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  182. 643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  183. 92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  184. 1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  185. 1042 EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN INTERFERON-ALFA TREATMENT NAIVE PATIENTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  186. 1045 SAFETY AND ANTIVIRAL EFFICACY OF 14 DAYS OF THE CYCOPHILIN INHIBITOR NIM811 IN COMBINATION WITH PEGYLATED INTERFERON α2a IN RELAPSED GENOTYPE 1 HCV INFECTED PATIENTS

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  187. 1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  188. 14 EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Eric J Lawitz

  189. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

    Article • Journal of Hepatology, August 2008, Elsevier

    Professor Eric J Lawitz

  190. 162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial

    Article • Gastroenterology, April 2008, Elsevier

    Professor Eric J Lawitz

  191. 996 TREATMENT WEEK 12 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAIVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS

    Article • Journal of Hepatology, January 2008, Elsevier

    Professor Eric J Lawitz

  192. 104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

    Article • Journal of Hepatology, January 2008, Elsevier

    Professor Eric J Lawitz

  193. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

    Article • Hepatology, October 2007, Wiley

    Professor Eric J Lawitz

  194. [783] SHORT-TERM ANTIVIRAL ACTIVITY AND SAFETY OF ACH-806 (GS-9132), AN NS4A ANTAGONIST, IN HCV GENOTYPE 1 INFECTED INDIVIDUALS

    Article • Journal of Hepatology, April 2007, Elsevier

    Professor Eric J Lawitz

  195. [14] CLEARANCE OF HCVRNA WITH VALOPICITABINE (NM) PLUS PEG-INTERFERON IN TREATMENT-NAIVE PATIENTS WITH HCV-1 INFECTION: RESULTS AT 24 AND 48 WEEKS

    Article • Journal of Hepatology, April 2007, Elsevier

    Professor Eric J Lawitz

  196. 28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates Robust Antiviral Effects

    Article • Gastroenterology, September 2006, Elsevier

    Professor Eric J Lawitz

  197. 111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus

    Article • Journal of Hepatology, April 2006, Elsevier

    Professor Eric J Lawitz

  198. O.078 Valopicitabine (NM283) plus peg-interferon for chronic hepatitis C in treatment naïve and nonresponder patients: interim phase IIb results

    Article • Journal of Clinical Virology, January 2006, Elsevier

    Professor Eric J Lawitz

  199. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study

    Article • BMC Gastroenterology, April 2005, Springer Science + Business Media

    Professor Eric J Lawitz

  200. A Pilot Study of Interleukin-11 in Subjects with Chronic Hepatitis C and Advanced Liver Disease Nonresponsive to Antiviral Therapy

    Article • The American Journal of Gastroenterology, December 2004, Nature

    Professor Eric J Lawitz

  201. Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti

    Article • BMC Gastroenterology, December 2004, Springer Science + Business Media

    Professor Eric J Lawitz

  202. Differences in treatment outcome for hepatitis C among ethnic groups

    Article • The American Journal of Medicine, August 2004, Elsevier

    Professor Eric J Lawitz

  203. Predictors of Oxygen Desaturation During Routine Gastrointestinal Endoscopy

    Article • Gastrointestinal Endoscopy, April 2004, Elsevier

    Professor Eric J Lawitz

  204. Treatment of Acute Hepatitis C Virus Infection in a Black Patient with Pegylated Interferon-a plus Ribavirin.

    Article • Southern Medical Journal, November 2003, Southern Medical Association

    Professor Eric J Lawitz

  205. Hepatic steatosis on ultrasound: Associated factors and relationship with steatosis on liver biopsy

    Article • Gastroenterology, April 2003, Elsevier

    Professor Eric J Lawitz

  206. Interleukin-11 in patients with chronic hepatitis C and advanced liver disease who have been nonresponsive to antiviral therapy

    Article • Gastroenterology, April 2003, Elsevier

    Professor Eric J Lawitz

  207. Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy

    Article • Gastroenterology, April 2003, Elsevier

    Professor Eric J Lawitz

  208. Treatment of chronic hepatitis C in nonresponders to previous therapy

    Article • Current Gastroenterology Reports, January 2003, Springer Science + Business Media

    Professor Eric J Lawitz

  209. 1120 Hepatitis C treatment practice patterns in the United States: a national survey

    Article • Hepatology, January 2003, Elsevier

    Professor Eric J Lawitz

  210. 997 Triple therapy compared to standard pegylated interferon alfa 2B + weight based ribavirin for treatment naive chronic hepatitis C[tri-star trial]: final results

    Article • Hepatology, January 2003, Elsevier

    Professor Eric J Lawitz

  211. 1190 Diabetes mellitus of new onset during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial

    Article • Hepatology, January 2003, Elsevier

    Professor Eric J Lawitz

  212. 1209 Triple therapy compared to standard Pegylated interferon alfa 2B + weight based ribavirin for previous nonresponders and relapsers with chronic hepatitis C

    Article • Hepatology, January 2003, Elsevier

    Professor Eric J Lawitz

  213. Continuous combination therapy has superior viral clearance compared to standard combination therapy-A multicenter, randomized trial

    Article • Gastroenterology, April 2001, Elsevier

    Professor Eric J Lawitz

  214. Continuous combination therapy has superior viral clearance compared to standard combination therapy-A multicenter, randomized trial

    Article • Gastroenterology, April 2001, Elsevier

    Professor Eric J Lawitz

  215. Failure of induction dosing of interferon to alter sustained response rates in patients with chronic hepatitis C

    Article • The American Journal of Gastroenterology, September 2000, Nature

    Professor Eric J Lawitz

  216. Comparison of daily induction dose interferon alpha 2b plus ribavirin followed by daily combination therapy versus standard combination therapy in treatment naive patients with chronic hepatitis C

    Article • Gastroenterology, April 2000, Elsevier

    Professor Eric J Lawitz

  217. Management of chronic hepatitis C: Effect of duration of retreatment after monotherapy failure

    Article • Gastroenterology, April 2000, Elsevier

    Professor Eric J Lawitz

  218. Screening and treatment of depression in chronic hepatitis C patients receiving interferon alpha-2b and ribavirin therapy

    Article • Gastroenterology, April 2000, Elsevier

    Professor Eric J Lawitz

  219. 6969 Outcome of rescreening patients referred for open access flexible fiberoptic sigmoidoscopy.

    Article • Gastrointestinal Endoscopy, April 2000, Elsevier

    Professor Eric J Lawitz

  220. Failure of interferon induction dosing to alter sustained response rates in patients with chronic hepatitis C

    Article • Gastroenterology, April 2000, Elsevier

    Professor Eric J Lawitz

  221. Treatment of hepatitis C with daily induction dose interferon alpha 2b plus ribavirin followed by daily combination therapy in patients who are treatment naïve or have previously failed an interferon based therapy

    Article • Gastroenterology, April 2000, Elsevier

    Professor Eric J Lawitz

  222. Response

    Article • Gastrointestinal Endoscopy, June 1999, Elsevier

    Professor Eric J Lawitz

  223. Utility of preoperative fiberoptic flexible sigmoidoscopy in the evaluation of patients with suspected gynecologic malignancy

    Article • Gastrointestinal Endoscopy, May 1998, Elsevier

    Professor Eric J Lawitz

  224. Utility of the preoperative fiberoptic flexible sigmoidoscopy (FFS) in the evaluation of patients with suspected gynecologic malignancy

    Article • Gastrointestinal Endoscopy, April 1996, Elsevier

    Professor Eric J Lawitz